Ten years of substantial work by Université de Montréal immunologist Nathalie Labrecque's team at the Montreal Clinical ...
Stock analysts at StockNews.com initiated coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Free Report) in a note issued to investors on Wednesday. The brokerage set a “sell” rating on the ...
Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 anticipated to be Presented in MayInitial Results From First Two ...
The HZI team has developed an AI-powered computer model that, for the first time, reveals the aging process at the cellular ...
Expanding CRISPR's Potential Since its discovery, CRISPR (“Clustered Regularly Interspaced Short Palindromic Repeats”), which ...
Multiple presentations demonstrate that T-knife’s proprietary next-generation technologies address important challenges with ...
The Food and Drug Administration has approved more than 100 monoclonal antibodies to treat a range of diseases. Other ...
The arc of biotechnology is one of breakthroughs and struggles, writes Tim Hunt, CEO of the Alliance for Regenerative ...
It may be disturbing to characterize human bodies in such commodifying terms, but the unavoidable reality is that human ...
The pathogen C. diff—the most common cause of health care-associated infectious diarrhea—can use a compound that kills the ...
News-Medical.Net on MSN5h
C. diff uses toxic compound to gain competitive advantage in the gutThe pathogen C. diff - the most common cause of health care-associated infectious diarrhea - can use a compound that kills ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback